Cabaletta Bio, Inc.

Cellares became the first company to announce receipt of an Advanced Manufacturing Technology designation from the US FDA on 1 April 2025, almost three years after the FDA Omnibus Reform Act of 2022 c

Companies looking to bring the first CAR-T treatment for autoimmune diseases to market will present their latest data at the European Alliance of Associations for Rheumatology (EULAR) meeting this wee

CRISPR Therapeutics AG ’s decision to transition from two earlier gene-edited allogeneic CAR-T cell therapies to next-generation candidates may have come at an opportune time, as concerns have arisen

One of the initial reactions to news that the US Food and Drug Administration is investing reports of T-cell malignancies in patients treated with approved CD19- and BCMA-targeting chimeric antigen re